Assertio (NASDAQ:ASRT) Upgraded to C- by TheStreet

TheStreet upgraded shares of Assertio (NASDAQ:ASRTGet Rating) from a d rating to a c- rating in a research report report published on Wednesday, TheStreetRatingsTable reports.

ASRT has been the topic of several other research reports. upgraded Assertio from a buy rating to a strong-buy rating in a report on Wednesday, June 15th. BWS Financial initiated coverage on shares of Assertio in a research note on Wednesday, May 18th. They issued a buy rating on the stock.

Assertio Stock Down 0.2 %

Assertio stock opened at $3.99 on Wednesday. The company has a 50-day simple moving average of $3.13 and a 200-day simple moving average of $2.77. The firm has a market capitalization of $181.28 million, a P/E ratio of 66.50, a P/E/G ratio of 0.90 and a beta of 1.60. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.83 and a current ratio of 0.90. Assertio has a one year low of $0.85 and a one year high of $4.14.

Assertio (NASDAQ:ASRTGet Rating) last issued its quarterly earnings results on Monday, May 9th. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.11. Assertio had a net margin of 2.68% and a return on equity of 3.21%. The company had revenue of $36.54 million during the quarter, compared to the consensus estimate of $33.07 million. During the same period in the prior year, the company earned $0.12 EPS. As a group, equities analysts expect that Assertio will post 0.4 earnings per share for the current year.

Insider Buying and Selling

In other news, Director James L. Tyree sold 44,643 shares of the business’s stock in a transaction dated Thursday, May 12th. The stock was sold at an average price of $2.36, for a total transaction of $105,357.48. Following the completion of the transaction, the director now directly owns 210,451 shares in the company, valued at approximately $496,664.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Assertio

Several institutional investors have recently bought and sold shares of ASRT. Russell Investments Group Ltd. acquired a new position in shares of Assertio during the 2nd quarter worth approximately $28,000. Advisor Group Holdings Inc. lifted its position in shares of Assertio by 2,983.7% during the 1st quarter. Advisor Group Holdings Inc. now owns 13,229 shares of the company’s stock valued at $38,000 after acquiring an additional 12,800 shares during the period. Cambridge Investment Research Advisors Inc. bought a new stake in shares of Assertio during the 4th quarter valued at $31,000. Mandatum Life Insurance Co Ltd bought a new stake in shares of Assertio during the 2nd quarter worth $44,000. Finally, Atria Wealth Solutions Inc. bought a new stake in shares of Assertio during the 1st quarter worth $43,000. Institutional investors own 15.64% of the company’s stock.

Assertio Company Profile

(Get Rating)

Assertio Holdings, Inc, a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.

Read More

Want More Great Investing Ideas?

Receive News & Ratings for Assertio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assertio and related companies with's FREE daily email newsletter.